Shanghai Acebright Pharmaceuticals Group Co., Ltd.

Shanghai Cdymax Pharmaceuticals Co., Ltd.

Shanghai Forefront Pharmaceutical Co., Ltd.

Jiangsu Cdymax Pharmaceuticals Co., Ltd.

Chengjun Huang

Wei Zhang

Yi Ren

Gang Fu

Yanyan Zhu

Zhewen Wei

Xiaoxia An

Shaojun Fu

Fengwang Mao

The present invention relates to a novel Ledipasvir (LDV) crystal form and a preparation method thereof. Specifically, disclosed is an LDV solvate. The solvate is a solvate formed by LDV and a solvent A and/or a solvent B, wherein the solvent A is acetonitrile or acetone; and the solvent B is methyl tertiary butyl ether (MTBE). Also disclosed are a preparation method and an application of the solvate. The solvate has a high purity, a good crystallization property, and better optical stability. The preparation method is simple and the process is stable. The solvate can significantly improve quality control and industrial applications of LDV-containing drugs.

Ledipasvir crystal form and preparation method thereof

Provided are acetaic abiraterone trifluoroacetate, a preparation method and an application of same. The acetaic abiraterone trifluoroacetate is obtained through a salt-forming reaction between acetaic Abiraterone and trifluoroacetic acid. The acetaic abiraterone trifluoroacetate undergoes self-purification through recrystallization, and dissociation and recrystallization are performed on the purified abiraterone acetate trifluoroacetate, so that the obtained acetaic abiraterone has a high purity, a high yield and stable quality, and is capable of meeting the requirement for mass production of acetaic abiraterone.

Acetatic abiraterone trifluoroacetate and preparation method and application of same

Growing community of inventors

Shanghai, China

Chengjun Huang